Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Gesynta Pharma AB logo — company profile

Gesynta Pharma AB

Founded 2017 Sweden Sweden 14 employees Series C Total: $196.00M Biopharma, Health Care +1

General Information

Company Name Gesynta Pharma AB
Founded Year 2017
Location Sweden Sweden +1
Employees 14
Industries Biopharma, Health Care, Pharmaceutical
Funding Stage Series C
Social

Get notified when Gesynta Pharma AB moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Gesynta Pharma AB

Gesynta Pharma AB is a Swedish biopharmaceutical company founded in 2017. The company focuses on addressing unmet medical needs, particularly in the Biopharma, Health Care, and Pharmaceutical sectors. Their flagship drug candidate, vipoglanstat (GS-248), is currently in clinical phase II development for the treatment of endometriosis, a chronic inflammatory disease affecting 10 percent of women of reproductive age. The company's second drug candidate, GS-073, also targets chronic inflammatory pain with a similar mode of action as vipoglanstat. The research and development efforts of Gesynta Pharma are based on collaboration with the Karolinska Institutet. Notable investors such as Industrifonden, Hadean Partners, and Linc AB have shown confidence in the company, with a kr190.00M Series C investment in 07 July 2020. Gesynta Pharma's focus on addressing medical needs with innovative drug candidates and strong investor backing positions the company as a promising player in the biopharmaceutical industry.

Taxonomy: Gesynta Pharma, drug development, endometriosis treatment, mPGES-1 inhibition, clinical phase II, chronic inflammatory pain, Karolinska Institutet, pharmacological target, unmet medical need, major shareholders, life science entrepreneurship, clinical phase I, microsomal prostaglandin E synthase-1

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series C •••••• 3
Investor Investor Investor
07 Jul 2020
Seed Round •••••• 1
Investor
05 Apr 2019

Gesynta Pharma AB Alternatives & Competitors

Gesynta Pharma AB vs
Himuka AM Pharma / Himuka AM Australia
Himuka AM Pharma / Himuka AM Australia Japan

Himuka is a clinical-stage biotech company, and conducting a Phase 1 clinical trial in Australia.

Corporate Round
1 employees
Digital Health, Health Care
Gesynta Pharma AB vs
Molecure
Molecure Poland

Fate can be altered.

Post Ipo Secondary
85 employees
Biopharma, Biotechnology
Gesynta Pharma AB vs
CytRx
CytRx

Driving Oncology Innovation with Advanced Chemotherapeutic Solutions

Post Ipo Equity
Biopharma, Biotechnology

FAQ About Gesynta Pharma AB

Gesynta Pharma's drug candidate vipoglanstat (GS-248) is in clinical phase II development for the treatment of endometriosis – a painful, chronic inflammatory disease that affects about 10 percent of women of reproductive age. Endometriosis often leads to severely reduced quality of life, and curren...
Gesynta Pharma AB was founded in 2017.
Gesynta Pharma AB is headquartered in Sweden.
Gesynta Pharma AB operates in the following industries: Biopharma, Health Care, Pharmaceutical.
Gesynta Pharma AB has approximately 14 employees.
Gesynta Pharma AB has completed 2 funding rounds, raising a total of $196.00M. The latest funding stage is Series C.
Top alternatives and competitors to Gesynta Pharma AB include Himuka AM Pharma / Himuka AM Australia, Molecure, CytRx, Endevica Bio, Apexigen. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Gesynta Pharma AB and Himuka AM Pharma / Himuka AM Australia are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Gesynta Pharma AB and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes